UndisclosedStrategic acquisitionHealthcare & Life Sciences
Lilly agrees to acquire blood-cancer biotech Calytrix Bio
Eli Lilly signed a definitive agreement to acquire Calytrix Bio, a Wellesley, Massachusetts biotech developing therapies for myeloproliferative neoplasms. Calytrix's lead preclinical asset is a biparatopic antibody targeting mutant calreticulin for essential thrombocythemia and myelofibrosis. Financial terms were not disclosed.
Why it matters: The deal broadens Lilly's presence in myeloproliferative neoplasms and builds on its existing blood-cancer capabilities.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →